<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Transcriptomics on Yige Wu, PhD</title>
    <link>http://localhost:4321/tags/transcriptomics/</link>
    <description>Recent content in Transcriptomics on Yige Wu, PhD</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 19 Feb 2026 00:00:00 +0000</lastBuildDate>
    <atom:link href="http://localhost:4321/tags/transcriptomics/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>The Trap of 1D Target Screening: Why Abundance Doesn&#39;t Predict Toxicity</title>
      <link>http://localhost:4321/blogs/erbb2-toxicity-screening/</link>
      <pubDate>Thu, 19 Feb 2026 00:00:00 +0000</pubDate>
      <guid>http://localhost:4321/blogs/erbb2-toxicity-screening/</guid>
      <description>&lt;h3 id=&#34;the-challenge&#34;&gt;The Challenge&lt;/h3&gt;&#xA;&lt;p&gt;During a recent technical discussion regarding on-target, off-tumor toxicity, we evaluated &lt;em&gt;ERBB2&lt;/em&gt; (HER2) as a case study. The standard practice in bioinformatics is to screen out targets with high normal-tissue expression using databases like GTEx (for RNA) or the Human Protein Atlas (for Protein).&lt;/p&gt;&#xA;&lt;p&gt;However, looking at the GTEx RNA-seq data, &lt;em&gt;ERBB2&lt;/em&gt; is highly abundant in the gastrointestinal tract (esophagus) and urinary bladder. Yet, the most famous, dose-limiting toxicities for HER2-targeted therapies (like Trastuzumab) are Cardiotoxicity and Interstitial Lung Disease (ILD)â€”tissues with comparatively unremarkable baseline RNA expression.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
